LRP1型
疾病
免疫疗法
低密度脂蛋白受体
受体
阿尔茨海默病
淀粉样蛋白(真菌学)
免疫系统
脂蛋白
低密度脂蛋白
医学
淀粉样前体蛋白
神经科学
生物
生物信息学
免疫学
内分泌学
胆固醇
内科学
病理
作者
Zhang Jun-chen,Wuhua Xu
出处
期刊:Chinese Journal of Neuromedicine
[Chinese Medical Association]
日期:2019-12-15
卷期号:18 (12): 1289-1293
标识
DOI:10.3760/cma.j.issn.1671-8925.2019.12.018
摘要
Almost all active immunotherapy attempts which targeted at clearing or reducing β-amyloid (Aβ) plaques in brains of patients with Alzheimer' disease (AD) were fallen into unprecedented difficulties, because of unsatisfactory curative effects. Recently, more and more evidences support that low density lipoprotein receptor related protein 1 (LRP1) is involved in Aβ production and clearance through multiple non-immune pathways, which has showed the potential as a whole-new interference target different with classical Aβ immunotherapies. So, we try to summarize the research developments of roles of LRP1 in Aβ metabolic process in physiological and AD conditions, and look forward to its possible applications in the prevention and treatment of AD.
Key words:
Alzheimer's disease; Low density lipoprotein receptor related protein 1; Beta-amyloid metabolism
科研通智能强力驱动
Strongly Powered by AbleSci AI